Sanofi and Regeneron's Dupixent becomes first biologic for kids under 12 with CSU

The FDA has approved Dupixent as the first biologic treatment for children ages two through eleven with uncontrolled chronic spontaneous urticaria, commonly known as CSU. The approval marks a significant advance for families dealing with a condition that has historically had limited treatment options for young children.

CSU is a condition characterized by persistent, recurring hives and intense itching that can last for six weeks or more. For children, the impact goes beyond physical discomfort — chronic itching and visible skin reactions can disrupt sleep, concentration at school, and social development. Standard treatments, typically antihistamines, often fail to provide adequate relief, leaving young patients and their parents searching for alternatives.

Dupixent, jointly developed by Sanofi and Regeneron, works by targeting specific proteins involved in allergic and inflammatory responses. The drug has already been approved for multiple conditions in adults and older children, including eczema, asthma, and certain sinus conditions. This latest expansion brings its benefits to a younger population that has had few targeted options.

The approval is based on clinical trial data demonstrating that Dupixent reduced itch severity and hive counts in pediatric patients whose CSU was not adequately controlled by antihistamines alone. For physicians who treat these cases, having a biologic option means being able to offer something beyond escalating doses of medications that simply are not working.

What This Means For You: If your child suffers from chronic hives that do not respond to standard allergy medications, this FDA approval opens a new treatment pathway worth discussing with their pediatrician or allergist. Dupixent is not an over-the-counter option — it requires a prescription and is administered by injection — but for families who have been cycling through ineffective treatments, it represents real hope. Talk to your doctor about whether this newly approved indication is appropriate for your child's specific situation.